Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
The second study, SOLAR-RECUR: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy.
- The second study, SOLAR-RECUR: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy.
- These clinical trials are currently enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year.
- Sakir Mutevelic, MD, Curium’s Chief Medical Officer said: “The successful start of patient enrollment is a significant step forward for Curium’s Phase 3 SOLAR-STAGE and SOLAR-RECUR clinical trials.
- We are pleased to announce the first patients enrolled and scanned were at XCancer® under the direction of Dr. Luke Nordquist.